Long-term hydroxyurea therapy alters bone marrow megakaryocyte morphology and associates with prognosis in myeloproliferative neoplasms
Annals of Hematology · 24.07.2026 · 105 (11)
DOI: 10.1007/s00277-026-07202-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 24.07.2026. Verfasst von Zhikang Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Bone Marrow, Hydroxyurea, Megakaryocytes, Myeloproliferative Disorders. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hydroxyurea (HU) is a first-line treatment for myeloproliferative neoplasms (MPNs), but a quantitative, standardized framework for assessing its impact on megakaryocyte (MK) morphology and prognosis remains lacking. This retrospective, two-center study analyzed 22,097 MKs from 280 patients (118 polycythemia vera [PV], 162 essential thrombocythemia [ET]), classified into 12 subtypes using the 5th edition WHO classification in conjunction with objectively derived thresholds (minimum P-value approach). Our primary contribution is to establish a quantifiable scoring framework that translates descriptive WHO categories into reproducible prognostic metrics. Using this framework, HU significantly reduced normal MK proportion in JAK2-ET ( P = 0.0189), TN-ET ( P = 0.0233), and JAK2-PV ( P = 0.0427), while increasing abnormal subtypes (bulbous, separated nuclear MKs); conversely, IFN was associated with preserved normal MKs and reduced abnormal forms. Multivariate Cox regression, applied to our empirically derived cutoffs, identified protective thresholds (normal MK ≥ 58% in ET, ≥ 53% in PV; emperipolesis ≥ 2% in ET) and adverse cutoffs (Naked nuclei ≥ 13% in ET, ≥ 7% in PV; staghorn like ≥ 6% in ET; separated nuclear ≥ 3% in ET) for myelofibrosis progression (all P < 0.05). Our quantitative findings corroborate prior qualitative observations that long-term HU is associated with adverse MK remodeling, while IFN correlates with lower progression risk as captured by our threshold-based system. This standardized scoring approach—not the identification of new prognostic factors—provides a reproducible tool for monitoring treatment-related morphological changes and may inform risk-adapted therapy in MPN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. househuang@zju.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zheng, Z., Xu, Y., Zeng, T., Li, R., Wen, B., Han, Q., Bao, X., & Huang, J. (2026). Long-term hydroxyurea therapy alters bone marrow megakaryocyte morphology and associates with prognosis in myeloproliferative neoplasms. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07202-x
Vancouver
Zheng Z, Xu Y, Zeng T, Li R, Wen B, Han Q, et al. Long-term hydroxyurea therapy alters bone marrow megakaryocyte morphology and associates with prognosis in myeloproliferative neoplasms. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07202-x
BibTeX
@article{Zheng2026,
author = {Zheng, Zhikang and Xu, Yingqing and Zeng, Tian and Li, Rumeng and Wen, Bingbing and Han, Qingmei and Bao, Xiaojing and Huang, Jian},
title = {Long-term hydroxyurea therapy alters bone marrow megakaryocyte morphology and associates with prognosis in myeloproliferative neoplasms},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07202-x}
}
EUVIMED